India Pharma Outlook Team | Friday, 10 October 2025
Thermo Fisher Scientific, has come up with a new lab test which needs to be developed locally, aimed at the better detection of lung transplant rejection and injury. The Molecular Microscope Diagnostic System for Lung (MMDx Lung) offers measurable insights that may facilitate diagnostic precision that allows the correct treatment to be given in time.
The risk of rejection is very high in lung transplant recipients; hence the requirement of frequent biopsies for their monitoring take place. Nevertheless, research shows that pathologists only 18% of the time agree on diagnoses when reading the same biopsy.
Analogous to the above fact, MMDx Lung through utilizing artificial intelligence to understand gene expression data from lung biopsies is supplying each sample with a comparison to a reference database that contains over 896 lung biopsies. The molecular scores it generates depict the levels of injury, graft dysfunction, and rejection, thus enabling more consistent and confident diagnoses to be possible.
This project was spearheaded by the Alberta Transplant Applied Genomics Center, with MMDx Lung designed to elevate the detection of rejection and Chronic Lung Allograft Dysfunction (CLAD), thereby, providing enhanced treatment and clinical research capabilities as a result.
Also Read: Bayer, Kumquat Launch Trial for KRAS G12D Cancer Drug
“MMDx Lung's launch represents an extension of our portfolio of post-transplant monitoring solutions and a testament to our dedication to personalizing patient care,” said Tina Liedtky, President of Transplant Diagnostics at Thermo Fisher.
In the U.S., the test will be available at Kashi Clinical Laboratories, which will be a new area of collaboration between Kashi and Thermo Fisher. It will cover lung, kidney, and heart transplant testing – facilitating clinical decision-making at a faster pace, thus, bettering transplant patients' outcomes.
